SEC Form 10-Q filed by Iterum Therapeutics plc
$ITRM
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/27/2021 | Sell → Hold | Gabelli & Co. | |
| 7/26/2021 | Buy → Neutral | HC Wainwright & Co. |
Gabelli & Co. upgraded Iterum Therapeutics from Sell to Hold
HC Wainwright & Co. downgraded Iterum Therapeutics from Buy to Neutral
Gabelli & Co upgraded Iterum Therapeutics from Sell to Hold
SC 13G/A - Iterum Therapeutics plc (0001659323) (Subject)
SC 13G - Iterum Therapeutics plc (0001659323) (Subject)
SC 13G - Iterum Therapeutics plc (0001659323) (Subject)
-- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2024. "With last month's approval of ORLYNVAHTM, we have renewed our outreach to potential strategic partners," said Corey Fishman, Iterum's Chief Executive Officer. "As the only oral penem antibiotic approved for commercial sa
DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Thursday, November 14, 2024. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access
Monday, October 28, 2024, at 8:30 a.m. EDT DUBLIN and CHICAGO, Oct. 28, 2024 /PRNewswire/ -- WHO: Iterum Therapeutics plc (NASDAQ:ITRM) is focused on deliveringdifferentiated anti-infectives aimed at combatting the global crisis of multi-drugresistant pathogens to significantly improve the lives of people affected byserious and life-threatening diseases around the world. WHAT: Conference call to discuss U.S. Food and Drug Administration (FDA) approval ofIterum's ORLYNVAH™ (Oral Sulopenem) for the treatment of uncomplicatedurinary tract infections (uUTIs).Speakers include: Co
Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has commenced its previously disclosed rights offering (the "Rights Offering"). Pursuant to the Rights Offering, the Company is distributing, at no charge, subscription rights to the Company's shareholders and holders of warrants that have contractual rights to participate in the Rights Offering which have not been waived (each, an "eligible warrant" and collectively, the "eligible warrants") as of 5:00 p.m., E
HC Wainwright & Co. analyst Ed Arce reiterates Iterum Therapeutics (NASDAQ:ITRM) with a Buy and maintains $6 price target.
8-K - Iterum Therapeutics plc (0001659323) (Filer)
10-Q - Iterum Therapeutics plc (0001659323) (Filer)
8-K - Iterum Therapeutics plc (0001659323) (Filer)
DUBLIN, Ireland and CHICAGO, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (the "Company" or "Iterum"), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Sailaja Puttagunta, M.D., to the newly created position of Chief Medical Officer, where she will oversee global clinical development and regulatory initiatives for Iterum. "We are thrilled that Sailaja is back at Iterum given her strong industry and operational leadership at a time when oral sulopenem is re-entering the clin
Patrick Heron to leave the Board DUBLIN, Ireland and CHICAGO, March 16, 2021 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Beth P. Hecht to the Company’s Board of Directors replacing Patrick Heron, who announced he would be leaving the Board, effective as of March 12, 2021. Ms. Hecht will also serve as a member of the Audit Committee and Compensation Committee of the Board. “I want to thank Patrick for his leade
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
4 - Iterum Therapeutics plc (0001659323) (Issuer)
DUBLIN and CHICAGO, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), (the Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that its deficiency under Listing Rule 5550(b) has been cured and that the Company is in compliance with applicable continued listing requirements. Based on the foregoing, the previously scheduled Nasdaq hearing before the Hearings Panel on November 21, has been cancelled. The Comp
-- ORLYNVAHTM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM), (Iterum), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2024. "With last month's approval of ORLYNVAHTM, we have renewed our outreach to potential strategic partners," said Corey Fishman, Iterum's Chief Executive Officer. "As the only oral penem antibiotic approved for commercial sa
DUBLIN and CHICAGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (NASDAQ:ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2024 financial results before the open of the U.S. financial markets on Thursday, November 14, 2024. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company's financial results and provide an update on its business. To access the call please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to Access